[12] Patent
[11] Patent No.:GC0009264  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2018                56/2018  
Number of the Decision to Grant the Patent:2018/140764
Date of the Decision to Grant the Patent:03/Dec/2018

[21] Application No.:GC 2015-29491

[22] Filing Date:1/6/2015

[30] Priority:

[33] State [32] Priority date [31] Priority No.
PCT
3/6/2014
PCT/IB2014/061901

[72] Inventors:1- Romain Siegrist،2- Bibia Heidmann،3- John Gatfield،4- Simon Stamm،5- Olivier Bezencon

[73] Owner: Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, CH-4123, Allschwil, Switzerland

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 31/415, 31/4155, 31/4439; A61P 15/00, 25/00, 3/10, 35/00, 9/00; C07D 231/40, 401/06, 401/12, 401/14, 403/12, 405/12, 405/14, 413/12, 471/04 (2006.01)

[56] Cited Documents:

-WO 2007/120729 A2 (MERCK & CO INC [US];BARROW JAMES C [US]; BIEBER KELLY-ANN S[US]; CUB) 25 October 2007  
Examiner: PH. Neda J. AlMuallem

[54] PYRAZOLE COMPOUNDS
[57] Abstract: The invention relates to compounds of formula (I) Formula (I)whereinX, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.
No. of claims: 25


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.